Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quinacrine in Advanced Renal Cell Carcinoma
NCT00574483Phase 2
Key facts
- Status
- Withdrawn
- Start
- Nov 2007
- Primary completion
- Jan 2008
- Countries
- 1
- Sponsor
- Cleveland BioLabs, Inc.
- Modality
- Small Molecules
- Drugs
- quinacrine
- Conditions
- renal cell carcinoma (RCC)
01
Overview
Phase 2, open-label, single-arm trial of quinacrine in renal cell carcinoma (RCC), sponsored by Cleveland BioLabs, Inc. Primary endpoint: Tumor response at 6 months. Planned start Nov 2007; status: withdrawn.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Quinacrine Arm
Quinacrine 100 mg/day
03
Who it enrols
Adult patients with metastatic or unresectable clear cell renal cell carcinoma who have received at least one prior systemic regimen.
04
Endpoints
Primary
Tumor response
Secondary
Time to tumor progression
Beyond the preview
Go deeper on NCT00574483.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00574483.